In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance.

ABSTRACT: In a biologic therapeutic landscape that requires versatility in targeting specificity, valency and half-life modulation, the monomeric Fc fusion platform holds exciting potential for the creation of a class of monovalent protein therapeutics that includes fusion proteins and bispecific targeting molecules. Here we report a structure-guided approach to engineer monomeric Fc molecules to adapt multiple versions of half-life extension modifications. Co-crystal structures of these monomeric Fc variants with Fc neonatal receptor (FcRn) shed light into the binding interactions that could serve as a guide for engineering the half-life of antibody Fc fragments. These engineered monomeric Fc molecules also enabled the generation of a novel monovalent bispecific molecular design, which translated t

SUBMITTER: Shan L 

PROVIDER: S-EPMC8426389 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature